Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John F Thompson

Showing results (361-370 of 569) with videos related to

Pageof 57
Sort By:
Pigment Cell & Melanoma Research|July 5, 2014
Protein signatures correspond to survival outcomes of AJCC stage III melanoma patientsSwetlana Mactier, Kimberley L Kaufman, Penghao Wang, et al.
Histopathology|December 28, 2018
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironmentTuba N Gide, Benjamin M Allanson, Alexander M Menzies, et al.
Annals of Surgery|February 22, 2013
The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomasSandro Pasquali, Lauren E Haydu, Richard A Scolyer, et al.
Clinical & Experimental Metastasis|January 18, 2014
Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patientsKimberley L Kaufman, Swetlana Mactier, Nicola J Armstrong, et al.
Annals of Surgical Oncology|October 29, 2014
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic MelanomaJohn F Thompson, Sanjiv S Agarwala, B Mark Smithers, et al.
Annals of Surgical Oncology|May 8, 2014
Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal diseaseAugustinus P T van der Ploeg, Lauren E Haydu, Andrew J Spillane, et al.
Annals of Surgery|February 28, 2012
Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanomaEsther Bastiaannet, Carin A Uyl-de Groot, Adrienne H Brouwers, et al.
The American Journal of Surgical Pathology|April 19, 2022
Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue NeviAndrew J Colebatch, Chandra Adhikari, Russell J Diefenbach, et al.
Annals of Surgical Oncology|May 10, 2015
Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single CenterLauren E Haydu, Joram T Stollman, Richard A Scolyer, et al.
Annals of Surgical Oncology|May 31, 2012
Evaluation of incomplete sentinel node biopsy procedures and sentinel node positivity rates as surgical quality-assurance parameters in melanoma patientsAndrew J Spillane, Lauren E Haydu, Nicholas C Lee, et al.
Pageof 57

Showing results (361-370 of 569) with videos related to

Sort By:
Pageof 57
Pigment Cell & Melanoma Research|July 5, 2014
Protein signatures correspond to survival outcomes of AJCC stage III melanoma patientsSwetlana Mactier, Kimberley L Kaufman, Penghao Wang, et al.
Histopathology|December 28, 2018
Inter- and intrapatient heterogeneity of indoleamine 2,3-dioxygenase expression in primary and metastatic melanoma cells and the tumour microenvironmentTuba N Gide, Benjamin M Allanson, Alexander M Menzies, et al.
Annals of Surgery|February 22, 2013
The importance of adequate primary tumor excision margins and sentinel node biopsy in achieving optimal locoregional control for patients with thick primary melanomasSandro Pasquali, Lauren E Haydu, Richard A Scolyer, et al.
Clinical & Experimental Metastasis|January 18, 2014
Surface antigen profiles of leukocytes and melanoma cells in lymph node metastases are associated with survival in AJCC stage III melanoma patientsKimberley L Kaufman, Swetlana Mactier, Nicola J Armstrong, et al.
Annals of Surgical Oncology|October 29, 2014
Phase 2 Study of Intralesional PV-10 in Refractory Metastatic MelanomaJohn F Thompson, Sanjiv S Agarwala, B Mark Smithers, et al.
Annals of Surgical Oncology|May 8, 2014
Melanoma patients with an unknown primary tumor site have a better outcome than those with a known primary following therapeutic lymph node dissection for macroscopic (clinically palpable) nodal diseaseAugustinus P T van der Ploeg, Lauren E Haydu, Andrew J Spillane, et al.
Annals of Surgery|February 28, 2012
Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanomaEsther Bastiaannet, Carin A Uyl-de Groot, Adrienne H Brouwers, et al.
The American Journal of Surgical Pathology|April 19, 2022
Comprehensive Clinical, Histopathologic, and Molecular Analysis and Long-term Follow-up of Patients With Nodal Blue NeviAndrew J Colebatch, Chandra Adhikari, Russell J Diefenbach, et al.
Annals of Surgical Oncology|May 10, 2015
Minimum Safe Pathologic Excision Margins for Primary Cutaneous Melanomas (1-2 mm in Thickness): Analysis of 2131 Patients Treated at a Single CenterLauren E Haydu, Joram T Stollman, Richard A Scolyer, et al.
Annals of Surgical Oncology|May 31, 2012
Evaluation of incomplete sentinel node biopsy procedures and sentinel node positivity rates as surgical quality-assurance parameters in melanoma patientsAndrew J Spillane, Lauren E Haydu, Nicholas C Lee, et al.
Pageof 57